Shield Therapeutics Secures FDA Approval Extension for ACCRUFeR in Pediatric Patients, Eyes China Market Entry in Q1 2026
核心洞察
The FDA has approved an expanded indication for ACCRUFeR (ferric maltol) to include pediatric patients aged 10 and above for iron deficiency (搜索) treatment, supported by positive Phase 3 FORTIS trial data.
Shield Therapeutics (搜索)' partner ASK plans to file for marketing authorization in China during Q1 2026, incorporating the pediatric trial data to strengthen the submission package.
The company has restructured its China licensing agreement with ASK, securing a $7.9M development milestone payment that will be used to settle obligations under the AOP Milestone Monetisation Agreement.
Shield Therapeutics (搜索) has achieved a significant regulatory milestone with the FDA's approval to extend ACCRUFeR's indication to include pediatric patients aged 10 and above for iron deficiency (搜索) treatment. The expanded approval, announced on December 22, 2025, positions the ferric maltol-based therapy as the first and only FDA-approved oral iron treatment for this patient population.
Pediatric Trial Success Drives Label Extension
The FDA's decision was supported by positive results from Shield's Phase 3 FORTIS/ST10-01-305 pediatric clinical trial, which demonstrated the efficacy, safety, and tolerability of a new oral liquid paediatric formulation in children aged one month and above with iron deficiency (搜索) presenting as iron deficiency anaemia. The trial utilized a ferric maltol suspension specifically designed for pediatric use.
Anders Lundstrom, CEO of Shield Therapeutics (搜索), commented: "We are delighted with the FDA approval of Accrufer, making it available to the adolescent population, who now can benefit from a much needed safe and effective oral iron treatment."
Shield plans to pursue further regulatory expansion, seeking an additional indication extension to include children aged one month and above alongside submission of a new drug application for the pediatric liquid formulation. If approved, the liquid formulation could also serve as an alternative for adult patients unable to swallow the current capsule formulation.
China Market Entry Accelerates
Shield's Chinese partner, Beijing Aosaikang Pharmaceutical Co. Ltd (搜索) (ASK), expects to submit marketing authorization to the China National Medical Products Administration (NMPA) for ACCRUFeR approval in Q1 2026. The submission will incorporate the positive pediatric Phase 3 data that supported the recent US FDA approval extension.
The companies have restructured their China License Agreement terms, with ASK agreeing to pay Shield a development milestone of $7.9M by January 31, 2026. Additional updated terms include a milestone of up to $3M linked to ACCRUFeR's final pricing in China and revised royalties of up to 10% based on annual net sales. These updated milestones replace the previous $11.4M milestone that was conditional upon marketing approval receipt.
Financial Restructuring Strengthens Position
Shield will use the $7.9M development milestone payment from ASK to settle all obligations under the AOP Milestone Monetisation Agreement and terminate the agreement. This payment represents a significant reduction from the amount that would have been due to AOP if the full $11.4M marketing approval milestone had been received.
Santosh Shanbhag, CFO at Shield, stated: "The amended terms of the agreement with ASK allows Shield to use the development milestone payment from ASK to fully cover the final payment due to AOP and terminate the AOP Milestone Monetisation Agreement earlier and at lower cost than previously planned. This further simplifies our capital structure and places Shield in a stronger financial position as we continue to execute our commercial strategy."
Market Opportunity and Therapeutic Impact
Iron deficiency (搜索) and iron deficiency with anemia affect approximately 20 million people in the US, representing a $2.3B market opportunity. As the first and only FDA-approved oral iron treatment for ID/IDA, ACCRUFeR addresses an important unmet medical need and currently holds the position as America's #1 branded prescription oral iron for ID/IDA according to IQVIA Xponent PlanTrak data.
ACCRUFeR (ferric maltol) features a novel, stable, non-salt-based formulation with a unique mechanism of absorption compared to other oral iron therapies. The drug has demonstrated efficacy and tolerability across multiple clinical trials and maintains patent coverage until the mid-2030s.